Sana Biotechnology, Inc. (SANA)
2.96
-0.12
(-3.90%)
USD |
NASDAQ |
Sep 24, 16:00
3.01
+0.05
(+1.69%)
Pre-Market: 09:20
Sana Biotechnology Research and Development Expense (Quarterly) : 36.08M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 36.08M |
| March 31, 2026 | 24.02M |
| December 31, 2025 | 37.38M |
| September 30, 2025 | 32.02M |
| June 30, 2025 | 30.87M |
| March 31, 2025 | 33.63M |
| December 31, 2024 | 30.78M |
| September 30, 2024 | 43.42M |
| June 30, 2024 | 36.30M |
| March 31, 2024 | 89.07M |
| December 31, 2023 | 48.54M |
| September 30, 2023 | 41.58M |
| June 30, 2023 | 64.78M |
| Date | Value |
|---|---|
| March 31, 2023 | 59.07M |
| December 31, 2022 | 41.50M |
| September 30, 2022 | 69.35M |
| June 30, 2022 | 68.58M |
| March 31, 2022 | 60.23M |
| December 31, 2021 | 50.48M |
| September 30, 2021 | 48.60M |
| June 30, 2021 | 40.95M |
| March 31, 2021 | 36.94M |
| December 31, 2020 | 32.74M |
| March 31, 2020 | 23.95M |
| December 31, 2019 | 28.54M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | 80.50M |
| Twist Bioscience Corp. | 18.02M |
| Beam Therapeutics, Inc. | 95.10M |
| Prime Medicine, Inc. | 33.40M |
| Revolution Medicines, Inc. | 392.47M |